GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Chugai Pharmaceutical Co Ltd (TSE:4519) » Definitions » Other Operating Expense

Chugai Pharmaceutical Co (TSE:4519) Other Operating Expense : 円-27,108 Mil (TTM As of Mar. 2024)


View and export this data going back to 1956. Start your Free Trial

What is Chugai Pharmaceutical Co Other Operating Expense?

Chugai Pharmaceutical Co's Other Operating Expense for the three months ended in Mar. 2024 was 円185 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2024 was 円-27,108 Mil.

Chugai Pharmaceutical Co's quarterly Other Operating Expense declined from Sep. 2023 (円-160 Mil) to Dec. 2023 (円-12,439 Mil) but then increased from Dec. 2023 (円-12,439 Mil) to Mar. 2024 (円185 Mil).

Chugai Pharmaceutical Co's annual Other Operating Expense increased from Dec. 2021 (円0 Mil) to Dec. 2022 (円64 Mil) but then declined from Dec. 2022 (円64 Mil) to Dec. 2023 (円-28,561 Mil).


Chugai Pharmaceutical Co Other Operating Expense Historical Data

The historical data trend for Chugai Pharmaceutical Co's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chugai Pharmaceutical Co Other Operating Expense Chart

Chugai Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 64.00 -28,561.00

Chugai Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,268.00 -14,694.00 -160.00 -12,439.00 185.00

Chugai Pharmaceutical Co Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-27,108 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chugai Pharmaceutical Co Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Chugai Pharmaceutical Co's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Chugai Pharmaceutical Co (TSE:4519) Business Description

Traded in Other Exchanges
Address
1-1 Nihonbashi-Muromachi 2-Chome, Nihonbashi Mitsui Tower (Reception15F), Chuo-ku, Tokyo, JPN, 103-8324
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding Ltd, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra for hemophilia A patients and tocilizumab for treating rheumatoid arthritis and COVID-19.

Chugai Pharmaceutical Co (TSE:4519) Headlines

No Headlines